Clinical trials: Paraneoplastic Syndromes
Blepharoptosis, Ptosis, Eyelid
Clinical Trial to Improve the Magnetic Levator Prosthesis
Blepharoptosis (incomplete opening of the eyelids) occurs because of a disruption in the normal agonist-antagonist neuro-muscular complex balance. An external device could restore eyelid movement.
- Conditions
- Blepharoptosis, Ptosis, Eyelid, Myasthenia Gravis, Stroke
- Trial name
- NCT03818204
- Testing
- Magnetic Levator Prosthesis (MLP)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Generalized Myasthenia Gravis, MG - Myasthenia Gravis
An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis
The purpose of this open-label study is to investigate the efficacy, safety, and tolerability of a continuous regimen of efgartigimod compared with a cyclic regimen in participants with Generalized Myasthenia Gravis (gMG).
- Conditions
- Generalized Myasthenia Gravis, MG - Myasthenia Gravis, gMG
- Trial name
- ADAPT NXT (NCT04980495)
- Testing
- Efgartigimod IV
- Where
- 39 sites in United States, Austria and 9 more
- Volunteers
- 69 people
- Sponsor
- argenx
Neuroblastoma, Opsoclonus-myoclonus
Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma
The purpose of this study is to evaluate the feasibility of giving four weekly doses of Rituximab (anti-CD20 antibody) in the treatment of children with refractory neuroblastoma associated opsoclonus-myoclonus.
- Trial name
- NCT00202930
- Testing
- anti-CD20 (Rituximab)
- Volunteers
- 4 people
- Sponsor
- Jean M. Tersak, M.D.
Epilepsy, Cryptogenic, Epilepsy, Partial
IVIG Treatment for Refractory Immune-Related Adult Epilepsy
The purpose of the initial screening study is to find out if immune problems are an unrecognized cause of epilepsy in some patients.
- Conditions
- Epilepsy, Cryptogenic, Epilepsy, Partial, Seizure Disorder, Autoimmune Diseases, Nervous System
- Trial name
- NCT01545518
- Testing
- IVIG
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Myasthenia Gravis
Myasthenia Gravis Inebilizumab Trial
Randomized, double-blind, placebo-controlled, Phase 3, parallel-group study with optional open-label extension.
- Trial name
- MINT (NCT04524273)
- Testing
- inebilizumab
- Where
- 104 sites in United States, Argentina and 17 more
- Volunteers
- 238 people
- Sponsor
- Amgen
Myasthenia Gravis
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
This is a randomized, double-blind, placebo-controlled, multicenter Phase II study to evaluate the safety, efficacy, and pharmacokinetics of ARGX-113 for the treatment of autoimmune Myasthenia Gravis (MG) with generalized muscle…
- Trial name
- NCT02965573
- Testing
- ARGX-113
- Where
- 19 sites in United States, Belgium and 6 more
- Volunteers
- 24 people
- Sponsor
- argenx
Myasthenia Gravis, Generalized
A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis
The primary objective is to evaluate whether IGIV-C improves MG symptoms as compared to placebo in subjects with MG.
- Trial name
- NCT02473952
- Testing
- IGIV-C
- Where
- 40 sites in United States, Belgium and 8 more
- Volunteers
- 62 people
- Sponsor
- Grifols Therapeutics LLC
Neuroendocrine Tumors
Capecitabine and Temozolomide for Neuroendocrine Cancers
This phase II study is designed to assess whether treatment with capecitabine/temozolomide (CAP/TEM) is safe and effective in treating subjects with progressive, differentiated, metastatic neuroendocrine tumors (NET).
- Trial name
- NCT00869050
- Testing
- Capecitabine, Temozolomide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Columbia University
Primary Lung Cancer, Benign Lung Disease
SP Thoracic IDE Study
To confirm the safety and performance of the da Vinci SP Surgical System, Instruments and Accessories in pulmonary lobectomy, and in thymectomy procedures.
- Conditions
- Primary Lung Cancer, Benign Lung Disease, Thymoma, Myasthenia Gravis
- Trial name
- NCT05150210
- Testing
- Robotic-Assisted Surgery
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Intuitive Surgical
Zollinger-Ellison Syndrome
YF476 and Type II Gastric Carcinoids
This study will evaluate whether treatment with YF476 is safe and effective in reducing the size of type II gastric carcinoid tumours, or limiting the abnormal growth of gastric ECL cells, in patients with Zollinger-Ellison…
- Trial name
- NCT02454075
- Testing
- YF476
- Volunteers
- 3 people
- Sponsor
- Trio Medicines Ltd.
Myasthenia Gravis
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
The specific primary objective of this study is to determine whether rituximab is a safe and beneficial therapeutic for Myasthenia Gravis (MG) that warrants further study in a phase III efficacy trial.
- Trial name
- NCT02110706
- Testing
- Rituximab
- Where
- 26 sites in United States
- Volunteers
- 52 people
- Sponsor
- Yale University
Generalized Myasthenia Gravis
A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.
This is a Long-Term, Single-Arm, Open-Label, Multicenter Phase 3 follow-on trial of the ARGX-113-1704 study to evaluate the safety and tolerability of ARGX-113 in patients with gMG.
- Trial name
- ADAPT+ (NCT03770403)
- Testing
- ARGX-113
- Where
- 52 sites in United States, Belgium and 13 more
- Volunteers
- 151 people
- Sponsor
- argenx
Generalized Myasthenia Gravis
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
The purpose of the MycarinGstudy is to evaluate the long-term safety, tolerability and long-term efficacy of rozanolixizumab in study participants with generalized myasthenia gravis (MG).
- Trial name
- NCT04124965
- Testing
- Rozanolixizumab
- Where
- 43 sites in United States, Canada and 10 more
- Volunteers
- 71 people
- Sponsor
- UCB Biopharma SRL
Myasthenia Gravis, Myasthenia Gravis, Juvenile Form
A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of eculizumab in the treatment of pediatric refractory gMG based on change from Baseline in the Quantitative Myasthenia Gravis…
- Conditions
- Myasthenia Gravis, Myasthenia Gravis, Juvenile Form, Myasthenia Gravis, Generalized
- Trial name
- NCT03759366
- Testing
- Eculizumab
- Where
- 11 sites in United States, Japan
- Volunteers
- 12 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Myasthenia Gravis
Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy
The purpose of this trial is to determine if thymectomy combined with prednisone therapy is more beneficial in treating non-thymomatous myasthenia gravis than prednisone therapy alone.
- Trial name
- NCT00294658
- Testing
- thymectomy plus prednisone, prednisone alone
- Where
- 70 sites in United States, Argentina and 16 more
- Volunteers
- 126 people
- Sponsor
- University of Alabama at Birmingham
Generalized Myasthenia Gravis
An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
A randomized, double-blind, placebo controlled, multicenter Phase 3 trial to evaluate the efficacy, safety, tolerability, quality of life and impact on normal daily activities of ARGX-113 in patients with gMG.
- Trial name
- ADAPT (NCT03669588)
- Testing
- ARGX-113
- Where
- 66 sites in United States, Belgium and 14 more
- Volunteers
- 167 people
- Sponsor
- argenx